Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Research groups

Elliot Abbott

PhD Researcher

Personalised radionuclide therapy of liver tumours

Injecting 90Y-loaded microspheres into liver tumours by their blood supply is called selective internal radiotherapy (SIRT). SIRT benefits patients because the absorbed radiation dose is better tolerated in the liver than from conventional external beam radiotherapy (EBRT). However, while EBRT dose is prescribed in advance, SIRT dose can only be measured after it has been delivered. To address this limitation, a personalised approach is needed.

Elliot's work aims to personalise SIRT by investigating:

  • clinical outcomes based on absorbed dose from SIRT
  • the radiobiology of SIRT compared to EBRT
  • topping-off undertreated areas from SIRT with EBRT
  • emerging noninvasive imaging techniques of blood perfusion to predict SIRT dose

Recent publications

More publications